1. Home
  2. CNEY vs SHPH Comparison

CNEY vs SHPH Comparison

Compare CNEY & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

N/A

Current Price

$0.45

Market Cap

2.4M

Sector

Industrials

ML Signal

N/A

Logo Shuttle Pharmaceuticals Holdings Inc.

SHPH

Shuttle Pharmaceuticals Holdings Inc.

N/A

Current Price

$5.26

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNEY
SHPH
Founded
2009
2012
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.1M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
CNEY
SHPH
Price
$0.45
$5.26
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 330.7K
36.5K
Earning Date
02-17-2027
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.38
52 Week High
$2.63
$8.88

Technical Indicators

Market Signals
Indicator
CNEY
SHPH
Relative Strength Index (RSI) 44.65 57.55
Support Level $0.44 $2.98
Resistance Level $0.62 $5.95
Average True Range (ATR) 0.05 0.47
MACD 0.01 -0.03
Stochastic Oscillator 51.12 75.63

Price Performance

Historical Comparison
CNEY
SHPH

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About SHPH Shuttle Pharmaceuticals Holdings Inc.

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.

Share on Social Networks: